• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Attitudes among dermatologists regarding actinic keratosis treatment options.皮肤科医生对光化性角化病治疗方案的态度。
Dermatol Reports. 2022 Jan 31;14(3):9392. doi: 10.4081/dr.2022.9392. eCollection 2022 Sep 14.
2
A trial-based cost-effectiveness analysis of topical 5-fluorouracil vs. imiquimod vs. ingenol mebutate vs. methyl aminolaevulinate conventional photodynamic therapy for the treatment of actinic keratosis in the head and neck area performed in the Netherlands.在荷兰进行的一项基于试验的成本效益分析,比较了局部使用5-氟尿嘧啶、咪喹莫特、鬼臼毒素和甲基氨基乙酰丙酸传统光动力疗法治疗头颈部光化性角化病的效果。
Br J Dermatol. 2020 Oct;183(4):738-744. doi: 10.1111/bjd.18884. Epub 2020 Feb 19.
3
[Not Available].[无可用内容]。
Ann Dermatol Venereol. 2019 May;146 Suppl 2:IIS22-IIS30. doi: 10.1016/S0151-9638(19)30202-9.
4
Treatment of Actinic Keratosis: The Best Choice through an Observational Study.光化性角化病的治疗:一项观察性研究中的最佳选择
J Clin Med. 2022 Jul 7;11(14):3953. doi: 10.3390/jcm11143953.
5
A cost-utility analysis of ingenol mebutate gel for the treatment of actinic keratosis: a Scottish perspective.咪喹莫特凝胶治疗光化性角化病的成本效用分析:苏格兰视角
Eur J Health Econ. 2016 Apr;17(3):287-304. doi: 10.1007/s10198-015-0679-8. Epub 2015 Mar 21.
6
How to treat actinic keratosis? An update.如何治疗光化性角化病?最新进展。
J Dermatol Case Rep. 2015 Jun 30;9(2):29-35. doi: 10.3315/jdcr.2015.1199.
7
Actinic keratosis - review for clinical practice.光化性角化病——临床实践综述。
Int J Dermatol. 2019 Apr;58(4):400-407. doi: 10.1111/ijd.14147. Epub 2018 Aug 2.
8
Physician-patient communication and patient-reported outcomes in the actinic keratosis treatment adherence initiative (AK-TRAIN): a multicenter, prospective, real-life study of treatment satisfaction, quality of life and adherence to topical field-directed therapy for the treatment of actinic keratosis in Italy.光化性角化病治疗依从性倡议(AK-TRAIN)中的医患沟通和患者报告结局:一项多中心、前瞻性、真实世界研究,评估了意大利局部场定向治疗光化性角化病的治疗满意度、生活质量和依从性。
J Eur Acad Dermatol Venereol. 2019 Jan;33(1):93-107. doi: 10.1111/jdv.15142. Epub 2018 Jul 8.
9
Actinic keratosis: a cross-sectional study of disease characteristics and treatment patterns in Danish dermatology clinics.光化性角化病:丹麦皮肤科诊所疾病特征与治疗模式的横断面研究
Int J Dermatol. 2016 Mar;55(3):309-16. doi: 10.1111/ijd.12874. Epub 2015 Aug 14.
10
Topical management of actinic keratosis and field cancerisation.光化性角化病和癌前病变的局部治疗。
G Ital Dermatol Venereol. 2009 Aug;144(4):459-62.

引用本文的文献

1
Trends in cutaneous squamous cell carcinoma on the lip incidence and mortality in the United States, 2000-2019.2000 - 2019年美国唇部皮肤鳞状细胞癌的发病率和死亡率趋势
Front Oncol. 2023 Apr 17;13:1111907. doi: 10.3389/fonc.2023.1111907. eCollection 2023.

本文引用的文献

1
Guidelines of care for the management of actinic keratosis.光化性角化病治疗管理指南。
J Am Acad Dermatol. 2021 Oct;85(4):e209-e233. doi: 10.1016/j.jaad.2021.02.082. Epub 2021 Apr 2.
2
Daylight Photodynamic Therapy: An Update.日光光动力疗法:更新。
Molecules. 2020 Nov 8;25(21):5195. doi: 10.3390/molecules25215195.
3
Use of complete clearance for assessing treatment efficacy for 5-fluorouracil interventions in actinic keratoses: how baseline lesion count can impact this outcome.使用完全清除率评估5-氟尿嘧啶干预治疗光化性角化病的疗效:基线病变计数如何影响这一结果。
J Mark Access Health Policy. 2020 Oct 9;8(1):1829884. doi: 10.1080/20016689.2020.1829884.
4
Italian expert consensus paper on the management of patients with actinic keratoses.意大利光化性角化病管理专家共识文件。
Dermatol Ther. 2020 Nov;33(6):e13992. doi: 10.1111/dth.13992. Epub 2020 Jul 27.
5
S3 guideline for actinic keratosis and cutaneous squamous cell carcinoma - short version, part 1: diagnosis, interventions for actinic keratoses, care structures and quality-of-care indicators.S3 光化性角化病和皮肤鳞状细胞癌指南 - 精简版,第 1 部分:诊断、光化性角化病干预、护理结构和护理质量指标。
J Dtsch Dermatol Ges. 2020 Mar;18(3):275-294. doi: 10.1111/ddg.14048.
6
Current therapies for actinic keratosis.光化性角化病的现行疗法。
Int J Dermatol. 2020 Jun;59(6):677-684. doi: 10.1111/ijd.14767. Epub 2020 Feb 3.
7
Efficacy of a film-forming medical device containing sunscreen (50+) and piroxicam 0.8% in actinic keratosis and field cancerization: a multicenter, assessor-blinded, 3 month trial.一种含有防晒霜(防晒指数50+)和0.8%吡罗昔康的成膜医疗设备治疗光化性角化病和场癌化的疗效:一项多中心、评估者盲法的3个月试验。
Curr Med Res Opin. 2017 Jul;33(7):1255-1259. doi: 10.1080/03007995.2017.1313212. Epub 2017 Apr 20.
8
The importance of treating the field in actinic keratosis.重视光化性角化病的治疗。
J Eur Acad Dermatol Venereol. 2017 Mar;31 Suppl 2:8-11. doi: 10.1111/jdv.14092.
9
Treatment considerations in actinic keratosis.光化性角化病的治疗考虑因素。
J Eur Acad Dermatol Venereol. 2017 Mar;31 Suppl 2:12-16. doi: 10.1111/jdv.14152.
10
British Association of Dermatologists' guidelines for the care of patients with actinic keratosis 2017.英国皮肤科医师协会2017年光化性角化病患者护理指南。
Br J Dermatol. 2017 Jan;176(1):20-43. doi: 10.1111/bjd.15107.

皮肤科医生对光化性角化病治疗方案的态度。

Attitudes among dermatologists regarding actinic keratosis treatment options.

作者信息

Moretta Gaia, Samela Tonia, Sampogna Francesca, Ricci Francesco, Carlesimo Fabio, Panebianco Annarita, D'Erme Angelo Massimiliano, Di Lella Giovanni, Pallotta Sabatino, Dellambra Elena, Abeni Damiano, Fania Luca

机构信息

IDI-IRCCS, Dermatological Research Hospital, Rome.

Unit of Dermatology, Livorno Hospital, Livorno, Italy.

出版信息

Dermatol Reports. 2022 Jan 31;14(3):9392. doi: 10.4081/dr.2022.9392. eCollection 2022 Sep 14.

DOI:10.4081/dr.2022.9392
PMID:36267162
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9577376/
Abstract

Actinic keratosis (AK) is considered a precancerous lesion that can develop into invasive squamous cell carcinoma. Its prevalence is increasing, and it is estimated that it affects between 1% and 44% of the adult population worldwide. Advanced age, fair skin phototypes, and cumulative sun exposure are the main risk factors for AK. Therapies for AK consists of lesion-directed treatment (, cryotherapy, curettage, electrocoagulation, and laser therapy) or field therapy [, photodynamic therapy (PDT), 5-fluorouracil (5-FU), diclofenac sodium (DIC), imiquimod (IMQ), and ingenol mebutate (Ing Meb)]. The type of therapy chosen is determined by the number and location of AKs, the patient's condition, and the patient's tolerability and compliance. In this survey, we collected information from 110 Italian dermatologists about their knowledge and attitudes toward various AK therapeutic approaches. In our study, we discovered that cryotherapy and PDT are the most used treatments for AK, while surgery and laser therapy are the least commonly used. The most commonly used topical therapies are DIC and IMQ 3.75 percent cream, followed by IMQ 5 percent cream, Ing Meb, and 5-FU. The correct treatment for AK can be difficult to choose, but adherence to therapy is critical for good results. Given the high and continuing rise in the incidence of AK, dermatologists' knowledge of various therapeutic approaches is critical.

摘要

光化性角化病(AK)被认为是一种癌前病变,可发展为浸润性鳞状细胞癌。其患病率正在上升,据估计,全球1%至44%的成年人口受其影响。高龄、白皙皮肤光型和累积日晒是AK的主要危险因素。AK的治疗方法包括病变定向治疗(如冷冻疗法、刮除术、电凝术和激光疗法)或区域治疗(如光动力疗法(PDT)、5-氟尿嘧啶(5-FU)、双氯芬酸钠(DIC)、咪喹莫特(IMQ)和鬼臼毒素酯(Ing Meb))。选择的治疗类型取决于AK的数量和位置、患者状况以及患者的耐受性和依从性。在这项调查中,我们收集了110名意大利皮肤科医生关于他们对各种AK治疗方法的知识和态度的信息。在我们的研究中,我们发现冷冻疗法和PDT是AK最常用的治疗方法,而手术和激光疗法使用最少。最常用的局部治疗药物是DIC和3.75%咪喹莫特乳膏,其次是5%咪喹莫特乳膏、Ing Meb和5-FU。AK的正确治疗方法可能难以选择,但坚持治疗对于取得良好效果至关重要。鉴于AK发病率持续大幅上升,皮肤科医生对各种治疗方法的了解至关重要。